We are thrilled to share the outstanding achievement of the Respiratory Clinical Research Team across the NICRF and NICRN in delivering the NIMBLE asthma trial with excellence and dedication.

What is NIMBLE?
NIMBLE is a Phase 3a, 52-week clinical study evaluating Depemokimab (GSK3511294) for patients with severe eosinophilic asthma who are transitioning from existing anti-IL-5 therapies.

Led by Expertise
The trial, led by Prof. Liam Heaney at the Belfast site and executed through a strong collaboration between the NICRF@ iREACH Health and NICRN.

Key Highlights
- Awarded Top Recruiter of July 2024.
- Participants attended up to 16 visits over 15 months.
- Clinical Research Organisation feedback: “Professional, responsive, and a pleasure to work with!”

This success underscores the NICRF and NICRN teams' commitment to excellence, regulatory compliance, and participant safety.

The NICRF and NICRN teamwork sets a benchmark for collaborative partnership work across the clinical research infrastructure in the delivery of clinical trials.